173 related articles for article (PubMed ID: 34928559)
21. Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic.
Patel NC; Crismon ML; Pondrom M
J Behav Health Serv Res; 2005; 32(4):438-45. PubMed ID: 16215452
[TBL] [Abstract][Full Text] [Related]
22. Drug treatment for patients with bipolar disorders in psychiatric practices in Germany in 2009 and 2018.
Bohlken J; Bauer M; Kostev K
Psychiatry Res; 2020 Jul; 289():112965. PubMed ID: 32388174
[TBL] [Abstract][Full Text] [Related]
23. Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study.
Fontanella CA; Campo JV; Phillips GS; Hiance-Steelesmith DL; Sweeney HA; Tam K; Lehrer D; Klein R; Hurst M
J Clin Psychiatry; 2016 May; 77(5):661-7. PubMed ID: 27249075
[TBL] [Abstract][Full Text] [Related]
24. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.
Taipale H; Mehtälä J; Tanskanen A; Tiihonen J
Schizophr Bull; 2018 Oct; 44(6):1381-1387. PubMed ID: 29272458
[TBL] [Abstract][Full Text] [Related]
25. [Mortality and cumulative exposure to antipsychotics, antidepressants and benzodiazepines in patients with schizophrenia: an observational follow-up study].
Tiihonenl J; Mittendorfer-Rutz E; Torniainen M; Alexanderson K; Tanskanen A
Duodecim; 2016; 132(2):181. PubMed ID: 26939492
[No Abstract] [Full Text] [Related]
26. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers.
Ritsner MS; Gibel A
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1442-52. PubMed ID: 16842897
[TBL] [Abstract][Full Text] [Related]
27. Utilization of Psychopharmacological Treatment Among Patients With Newly Diagnosed Bipolar Disorder From 2001 to 2010.
Chang CM; Wu CS; Huang YW; Chau YL; Tsai HJ
J Clin Psychopharmacol; 2016 Feb; 36(1):32-44. PubMed ID: 26650974
[TBL] [Abstract][Full Text] [Related]
28. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
[TBL] [Abstract][Full Text] [Related]
29. Real-world effectiveness of mood stabilizer use in schizophrenia.
Puranen A; Koponen M; Lähteenvuo M; Tanskanen A; Tiihonen J; Taipale H
Acta Psychiatr Scand; 2023 Mar; 147(3):257-266. PubMed ID: 36065482
[TBL] [Abstract][Full Text] [Related]
30. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.
Lafeuille MH; Grittner AM; Fortier J; Muser E; Fasteneau J; Duh MS; Lefebvre P
Am J Health Syst Pharm; 2015 Mar; 72(5):378-89. PubMed ID: 25694413
[TBL] [Abstract][Full Text] [Related]
31. Exposure to psychotropic medications and mortality in schizophrenia: a 5-year national cohort study.
Lin JY; Yeh LL; Pan YJ
Psychol Med; 2023 Sep; 53(12):5528-5537. PubMed ID: 36134676
[TBL] [Abstract][Full Text] [Related]
32. Hospital readmission in first-time admitted patients with schizophrenia: smoking patients had higher hospital readmission rate than non-smoking patients.
Kobayashi M; Ito H; Okumura Y; Mayahara K; Matsumoto Y; Hirakawa J
Int J Psychiatry Med; 2010; 40(3):247-57. PubMed ID: 21166336
[TBL] [Abstract][Full Text] [Related]
33. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Tiihonen J; Lönnqvist J; Wahlbeck K; Klaukka T; Niskanen L; Tanskanen A; Haukka J
Lancet; 2009 Aug; 374(9690):620-7. PubMed ID: 19595447
[TBL] [Abstract][Full Text] [Related]
34. Associations between the use of specific psychotropic drugs and all-cause mortality among older adults in Germany: Results of the mortality follow-up of the German National Health Interview and Examination Survey 1998.
Du Y; Wolf IK; Busch MA; Knopf H
PLoS One; 2019; 14(1):e0210695. PubMed ID: 30640945
[TBL] [Abstract][Full Text] [Related]
35. Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001-2008).
Sim K; Yong KH; Chan YH; Tor PC; Xiang YT; Wang CY; Lee EH; Fujii S; Yang SY; Chong MY; Ungvari GS; Si T; He YL; Chung EK; Chee KY; Trivedi J; Udomratn P; Shinfuku N; Kua EH; Tan CH; Sartorius N; Baldessarini RJ
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1157-64. PubMed ID: 21557883
[TBL] [Abstract][Full Text] [Related]
36. Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders.
Rømer Thomsen K; Thylstrup B; Pedersen MM; Pedersen MU; Simonsen E; Hesse M
Schizophr Res; 2018 May; 195():495-500. PubMed ID: 28965780
[TBL] [Abstract][Full Text] [Related]
37. Description of long-term polypharmacy among schizophrenia outpatients.
Suokas JT; Suvisaari JM; Haukka J; Korhonen P; Tiihonen J
Soc Psychiatry Psychiatr Epidemiol; 2013 Apr; 48(4):631-8. PubMed ID: 23007295
[TBL] [Abstract][Full Text] [Related]
38. Psychotropic drug use and mortality in old people with dementia: investigating sex differences.
Brännström J; Boström G; Rosendahl E; Nordström P; Littbrand H; Lövheim H; Gustafson Y
BMC Pharmacol Toxicol; 2017 May; 18(1):36. PubMed ID: 28545507
[TBL] [Abstract][Full Text] [Related]
39. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study.
Wimberley T; Støvring H; Sørensen HJ; Horsdal HT; MacCabe JH; Gasse C
Lancet Psychiatry; 2016 Apr; 3(4):358-66. PubMed ID: 26922475
[TBL] [Abstract][Full Text] [Related]
40. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
